MA34483B1 - Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante - Google Patents
Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulanteInfo
- Publication number
- MA34483B1 MA34483B1 MA35688A MA35688A MA34483B1 MA 34483 B1 MA34483 B1 MA 34483B1 MA 35688 A MA35688 A MA 35688A MA 35688 A MA35688 A MA 35688A MA 34483 B1 MA34483 B1 MA 34483B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- hypertension
- prevention
- heart failure
- anticoagulant therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des méthodes et des compositions pharmaceutiques pour le traitement de l'hypertension et/ou la prévention ou le traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante à l'aide d'un ou de plusieurs composés qui sont thérapeutiquement efficaces mais n'ont pas d'impact sur le ou les effets pharmacocinétiques ou pharmacodynamiques de l'anticoagulant, tels que la warfarine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37641710P | 2010-08-24 | 2010-08-24 | |
PCT/US2011/048542 WO2012027237A1 (fr) | 2010-08-24 | 2011-08-22 | Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34483B1 true MA34483B1 (fr) | 2013-08-01 |
Family
ID=44543868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35688A MA34483B1 (fr) | 2010-08-24 | 2011-08-22 | Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante |
Country Status (17)
Country | Link |
---|---|
US (2) | US20130158088A1 (fr) |
EP (1) | EP2608784B1 (fr) |
JP (1) | JP2013536230A (fr) |
KR (1) | KR101864865B1 (fr) |
CN (1) | CN103079554A (fr) |
AU (1) | AU2011293648B2 (fr) |
BR (1) | BR112013004192A2 (fr) |
CA (1) | CA2807830C (fr) |
CL (1) | CL2013000513A1 (fr) |
ES (1) | ES2702529T3 (fr) |
GT (1) | GT201300047A (fr) |
MA (1) | MA34483B1 (fr) |
MX (1) | MX341174B (fr) |
RU (1) | RU2564941C2 (fr) |
SG (1) | SG187755A1 (fr) |
TW (1) | TW201208678A (fr) |
WO (1) | WO2012027237A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200111822A (ko) | 2012-08-24 | 2020-09-29 | 노파르티스 아게 | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 |
JP2016530282A (ja) * | 2013-08-26 | 2016-09-29 | ノバルティス アーゲー | 新規使用 |
SI3038654T1 (sl) * | 2013-08-26 | 2020-02-28 | Novartis Ag | Nova uporaba |
CN105461647B (zh) * | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
CN105873586B (zh) | 2014-12-08 | 2019-09-13 | 苏州晶云药物科技股份有限公司 | 一种包含缬沙坦和ahu377的三钠盐超分子复合物的晶型及其制备方法 |
CN108601741B (zh) | 2016-02-03 | 2022-05-24 | 诺华股份有限公司 | 有机化合物的盖伦制剂 |
WO2017218418A1 (fr) * | 2016-06-13 | 2017-12-21 | The Board Of Regents Of The University Of Texas System | Compositions et procédés de modélisation de l'insuffisance cardiaque à fraction d'éjection conservée |
CA3110152A1 (fr) | 2018-08-23 | 2020-02-27 | Novartis Ag | Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque |
WO2020039394A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Nouvelles combinaisons de médicaments |
KR102215623B1 (ko) * | 2020-07-24 | 2021-02-15 | 유니셀랩 주식회사 | 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19675036I2 (de) | 1990-02-19 | 2004-10-21 | Novartis Ag | Acylverbindungen. |
US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
US6869357B2 (en) * | 2001-12-19 | 2005-03-22 | Igt | Methods of conducting games of chance and gaming devices with multiple pay lines |
US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
US7857515B2 (en) * | 2007-06-15 | 2010-12-28 | S.C. Johnson Home Storage, Inc. | Airtight closure mechanism for a reclosable pouch |
HRP20230178T3 (hr) * | 2007-11-06 | 2023-03-31 | Novartis Ag | Farmaceutski pripravci temeljeni na nadgradnjama antagonista/blokatora angiotenzinskog receptora (arb) i inhibitoru neutralne endopeptidaze (nep) |
-
2011
- 2011-08-22 US US13/818,346 patent/US20130158088A1/en not_active Abandoned
- 2011-08-22 AU AU2011293648A patent/AU2011293648B2/en active Active
- 2011-08-22 EP EP11751752.4A patent/EP2608784B1/fr not_active Revoked
- 2011-08-22 MA MA35688A patent/MA34483B1/fr unknown
- 2011-08-22 RU RU2013112859/15A patent/RU2564941C2/ru active
- 2011-08-22 BR BR112013004192A patent/BR112013004192A2/pt not_active IP Right Cessation
- 2011-08-22 KR KR1020137007278A patent/KR101864865B1/ko active IP Right Grant
- 2011-08-22 CA CA2807830A patent/CA2807830C/fr not_active Expired - Fee Related
- 2011-08-22 CN CN201180041154XA patent/CN103079554A/zh active Pending
- 2011-08-22 WO PCT/US2011/048542 patent/WO2012027237A1/fr active Application Filing
- 2011-08-22 JP JP2013526053A patent/JP2013536230A/ja not_active Withdrawn
- 2011-08-22 MX MX2013002212A patent/MX341174B/es active IP Right Grant
- 2011-08-22 ES ES11751752T patent/ES2702529T3/es active Active
- 2011-08-22 SG SG2013009352A patent/SG187755A1/en unknown
- 2011-08-23 TW TW100130147A patent/TW201208678A/zh unknown
-
2013
- 2013-02-22 GT GT201300047A patent/GT201300047A/es unknown
- 2013-02-22 CL CL2013000513A patent/CL2013000513A1/es unknown
-
2014
- 2014-07-21 US US14/336,244 patent/US20140329872A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX341174B (es) | 2016-08-10 |
US20140329872A1 (en) | 2014-11-06 |
KR101864865B1 (ko) | 2018-06-05 |
CN103079554A (zh) | 2013-05-01 |
SG187755A1 (en) | 2013-03-28 |
KR20130095754A (ko) | 2013-08-28 |
EP2608784A1 (fr) | 2013-07-03 |
MX2013002212A (es) | 2013-05-09 |
ES2702529T3 (es) | 2019-03-01 |
JP2013536230A (ja) | 2013-09-19 |
RU2013112859A (ru) | 2014-09-27 |
RU2564941C2 (ru) | 2015-10-10 |
AU2011293648A1 (en) | 2013-03-21 |
TW201208678A (en) | 2012-03-01 |
CA2807830C (fr) | 2018-04-03 |
BR112013004192A2 (pt) | 2016-05-10 |
GT201300047A (es) | 2014-07-08 |
US20130158088A1 (en) | 2013-06-20 |
AU2011293648B2 (en) | 2015-02-12 |
CA2807830A1 (fr) | 2012-03-01 |
CL2013000513A1 (es) | 2014-08-29 |
WO2012027237A1 (fr) | 2012-03-01 |
EP2608784B1 (fr) | 2018-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34483B1 (fr) | Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
MA40290A1 (fr) | Agents immunorégulateurs | |
MA47079B1 (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
NZ727849A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
MA42145B1 (fr) | Triazoles agonistes du récepteur apj | |
MA54231B1 (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
TN2010000154A1 (fr) | Composition destinee a la regulation du metabolism des lipides | |
EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
MA35804B1 (fr) | Modulation de l'expression du virus de l'hepatite b (vhb) | |
MA37808A1 (fr) | Composés et leurs utilisations thérapeutiques | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
MA38959A1 (fr) | Modulateurs du facteur b du complément | |
MA34474B1 (fr) | Agonistes de gpr40 | |
MA29444B1 (fr) | Antagonistes npy, preparation et utilisations | |
MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
MA32360B1 (fr) | Thérapie pour cancer hépatique | |
MA54386B1 (fr) | Modulateurs de trex1 | |
MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
MA43294A1 (fr) | Sels et promédicaments de 1-méthyl -d-tryptophane | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle |